GuidelineClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2018
SEOM clinical guideline for treatment of kidney cancer (2017).
Guideline in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Quality assessment of kidney cancer clinical practice guidelines using AGREE II instrument: A critical review.Medicine · 2019Pooled it
- Development and validation of a deep learning radiomics model for predicting capsular invasion in small renal masses: a multicenter retrospective study.Quantitative imaging in medicine and surgery · 2026Article
- Personalized survival predictions in chromophobe renal cell carcinoma: development of a machine learning-based web tool.International urology and nephrology · 2026Article
- Assessing the methodological strengths and limitations of the Spanish Society of Medical Oncology (SEOM) guidelines: a critical appraisal using AGREE II and AGREE-REX tool.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Localization of spleen and kidney organs from CT scans based on classification of slices in rotational views.Scientific reports · 2023Article
- The Role of Long Noncoding RNA (lncRNAs) Biomarkers in Renal Cell Carcinoma.International journal of molecular sciences · 2022Review
- A CT-based radiomics model for predicting renal capsule invasion in renal cell carcinoma.BMC medical imaging · 2022Article
- Clinical translation of immunomodulatory therapeutics.Advanced drug delivery reviews · 2021Review
- Long-term outcomes of CT-guided percutaneous cryoablation of T1a and T1b renal cell carcinoma.Diagnostic and interventional radiology (Ankara, Turkey) · 2021Article
- Analysis of expression, epigenetic, and genetic changes of HNF1B in 130 kidney tumours.Scientific reports · 2020Article
- Upregulation of lncRNA AGAP2-AS1 is an independent predictor of poor survival in patients with clear cell renal carcinoma.Oncology letters · 2020Article
- New Treatments in Renal Cancer: The AhR Ligands.International journal of molecular sciences · 2020Review
- Complex surgery and perioperative systemic therapy for genitourinary cancer of the retroperitoneum.Current oncology (Toronto, Ont.) · 2020Article
- 2017 SEOM guidelines: a multidisciplinary approach.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.